Lisa Laser’s product portfolio consists of laser hardware units, laser fibers, endoscopes and other accessories for laser-assisted surgery. The company has been developing surgical laser technologies consisting of both thulium and holmium lasers for the treatment of benign prostatic hyperplasia, since 1989. More than half of men in the United States will develop the condition by age 60, and 30 million already have it, according to the American Urological Association.
“Patient safety and positive surgical outcomes remain our top priority. Lisa Laser’s portfolio of electrically-silent, precision-based surgical therapies directly aligns with OmniGuide’s goal of benefiting patients through the preservation of healthy tissue during surgery, “ said John Buhler, CEO of OmniGuide, in a prepared statement.
“We are pleased to be joining the OmniGuide team as we combine both our thulium and holmium laser technologies with OmniGuide’s market-leading CO2 lasers and enhanced-safety flexible fibers,” said Heinrich-Otto Teichmann, managing partner of Lisa Laser. “As we strive to make tissue-sparing laser technology the global standard of care, we look forward to the innovation synergies presented by our combined capabilities.”
OmniGuide said it expects the acquisition to close in the third quarter of this year.